Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SC0191 Combination Chemotherapy in Advanced Ovarian Cancer
NCT06055348Phase 2Not yet recruiting
- Sponsor
- BioCity Biopharma
- Start
- Oct 2023
- Primary completion
- Aug 2025
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of sonkibartinib in ovarian cancer (2 arms), sponsored by BioCity Biopharma. Primary endpoints: Safety and Tolerability and Recommended Phase 2 Dose. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
sonkibartinib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT06055348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06055348.